Featured Posts

  

Dispatches From the Crossroads

Rss
Posted by: BIO Ventures for Global Health on 5/12/2011 | 1 Comment
A major theme of last week’s Global Vaccines 202X: Access, Equity, Ethics meeting, hosted by the Center for Vaccine Ethics and Policy (CVEP) in Philadelphia, was the value of evidence to support vaccine development and use. But what impact has evidence had on the vaccine community so far?
Categories: Meetings
Posted by: BIO Ventures for Global Health on 5/3/2011 | 0 Comments
After more than 100 years of silence, cholera returned to Haiti with a vengeance last year, infecting more than 230,000 people and claiming 4,500 lives. Although cholera has long plagued mankind, we have a tool today that wasn’t available to the people living on the banks of the Magdalena River in Gabriel García Márquez’s famous novel: a vaccine. So, why did so many die of cholera 20 years after the initial approval of a cholera vaccine? The answer (or at least part of it): the cholera vaccine was not deployed during the 2010 outbreak. Although the decision not to use the cholera vaccine in Haiti was complex, the challenges faced by the cholera vaccine have implications for other vaccines that are available today and for new vaccines for neglected disease that are still in development.
Categories: News

  

Recent Comments

by Chad on Coffee Break
"It is really sad that third-world countries suffer so much from an assortment of diseases and we tend to live without worrying about it. Only in a perfect world could the public and privates sectors work together as a "super-power" to recognize and fix these problems, but as of the current economic conditions it seems to be fading even more. Honestly, this is such a sad moment for everyone!" Read more »

by Yina on A Shifting Paradigm?
"As a long time agent of change in the Healthcare space, I have seen the under uliaizttion of technology. It is not bleeding edge' technology that causes me concern but the more mature ones that have been poorly driven and implemented. Much of this can be attributed to the Change Management plan. We fail to fully vet pilot sites, we jam data and processing into the pipe without taking avantage of future implementations, we include the directly affected stakeholders long after implementation starts and we don't analyze the impact on systems and layered products needed for success. The resourcing and uliaizttion of analysts, technical tactitions and workflow specialtists is arduous and expensive (and often considered unnecessary). However, the reengineering of applications and lost hours due to disruption at the user end needs to be added to the cost algorithm. After all even a medium sized system implementation failure creates grief for anyone else trying to affect change in the same user environment." Read more »

by Christian on Crossing the Valley of Death
"If the NIH could find a way to get the CAN funded then we could get some more research and development on the way. Congress just needs to approve the funding for this project. Thanks..." Read more »